Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents
Bioorganic & Medicinal Chemistry, ISSN: 0968-0896, Vol: 23, Issue: 9, Page: 2221-2240
2015
- 32Citations
- 53Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations32
- Citation Indexes32
- 32
- CrossRef31
- Captures53
- Readers53
- 53
Article Description
Falcipain-2 is a papain family cysteine protease and an emerging antimalarial drug target. A pseudo-tripeptide scaffold I was designed using in silico screening tools and the three dimensional structures of falcipain-2, falcipain-3, and papain. This scaffold was investigated at four positions, T 1, T 2, T 3, and T 3 ′, with various targeted substitutions to understand the structure–activity relationships. Inhibitor synthesis was accomplished by first obtaining the appropriate dipeptide precursors with common structural components. The pyrrolidine moiety introduced interesting rotamers in a number of synthesized molecules, which was confirmed using high-temperature 1 H NMR spectroscopy. Among the synthesized compounds, 61, 62, and 66 inhibited falcipain-2 activity with inhibition constants ( K i ) of 1.8 ± 1.1, 0.2 ± 0.1 and 7.0 ± 2.3 μM, respectively. A group of molecules with a pyrrolidine moiety at the T 2 position ( 68, 70, 71, 72, and 73 ) also potently inhibited falcipain-2 activity ( K i = 0.4 ± 0.1, 2.5 ± 0.5, 3.3 ± 1.1, 7.5 ± 1.9, and 4.6 ± 0.7 μM, respectively). Overall, compound 74 exhibited potent anti-parasitic activity (IC 50 = 0.9 ± 0.1 μM), corresponding with its inhibitory activity against falcipain-2, with a K i of 1.1 ± 0.1 μM. Compounds 62 and 67 inhibited the growth of the drug resistant parasite Dd2 with better efficacy, and compound 74 exhibited a 7- to 12-fold higher potency against Dd2 and MCamp isolates, than the laboratory strain (3D7). These data suggest that this novel series of compounds should be further investigated as potential antimalarial agents.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0968089615001789; http://dx.doi.org/10.1016/j.bmc.2015.02.062; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84937763108&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/25840796; https://linkinghub.elsevier.com/retrieve/pii/S0968089615001789; https://dx.doi.org/10.1016/j.bmc.2015.02.062
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know